TD-0903
0183
Phase 2 small_molecule completed
Quick answer
TD-0903 for Acute Lung Injury (ALI) Associated With COVID-19 is a Phase 2 program (small_molecule) at Theravance Biopharma with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Theravance Biopharma
- Indication
- Acute Lung Injury (ALI) Associated With COVID-19
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed